A PoTENtial Antidote: A Prohemostatic Factor Xa Variant for Reversal of Direct Oral Anticoagulants.
نویسندگان
چکیده
CIRCULATION RESEARCH (ISSN 0009-7330 print / 1524-4571 online) is published semimonthly for 24 total issues a year by Wolters Kluwer Health, Inc. at 14700 Citicorp Drive, Bldg 3, Hagerstown, MD 21742. Business offices are located at Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. AHA members will have online access to the journal as a benefit of membership. In the US, individuals may subscribe in print for their personal use at the annual rate of $749 for nonmembers. International: $888 for nonmembers. Online-only and other additional rates can be found online at http://lww.com/circres. AHA membership information can be found online at professional.heart.org. Periodicals postage paid at Hagerstown, MD, and additional mailing offices. POSTMASTER: Send address changes to Circulation Research, American Heart Association, Wolters Kluwer Health, Inc., PO Box 1610, Hagerstown, MD 21740. Hyperpolarized MRI of the Human Heart Cunningham et al. page 1177
منابع مشابه
Global assays and the management of oral anticoagulation
Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the principle of the test and the type of oral anticoagulant. Knowledge on coagulation tests applicable in monitoring status and reversal of oral anticoagulation is a prerequisite when studying po...
متن کاملAntidotes for novel oral anticoagulants: current status and future potential.
The direct thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, edoxaban, and apixaban are a new generation of oral anticoagulants. Their advantage over the vitamin K antagonists is the lack of the need for monitoring and dose adjustment. Their main disadvantage is currently the absence of a specific reversal agent. Dabigatran's, unlike the anti-Xa agents, absorption can be reduced...
متن کاملA PoTENtial Antidote
The direct oral anticoagulants (DOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, can be given in fixed doses without routine coagulation monitoring. In clinical trials, the DOACs have been shown to be at least as effective as vitamin K antagonists (VKAs), such as warfarin, for stroke prevention in nonvalvular atrial fibrillation and for treatment of venous thromboembolism,...
متن کاملProthrombin Complex Concentrate, a General Antidote for Oral Anticoagulation
Prothrombin complex concentrate (PCC) is used for the rapid reversal of vitamin K antagonist (VKA) anticoagulation. PCC is also applicable in situations requiring rapid reversal of anticoagulation by non-vitamin K antagonist direct thrombin and factor Xa inhibitor oral anticoagulants (NOACs), thereby making PCC a general antidote for oral anticoagulation. In this chapter, the composition of dif...
متن کاملThe Reversal of Direct Oral Anticoagulants in Animal Models
Several direct oral anticoagulants (DOACs), including direct thrombin and factor Xa inhibitors, have been approved as alternatives to vitamin K antagonist anticoagulants. As with any anticoagulant, DOAC use carries a risk of bleeding. In patients with major bleeding or needing urgent surgery, reversal of DOAC anticoagulation may be required, presenting a clinical challenge. The optimal strategy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Circulation research
دوره 119 11 شماره
صفحات -
تاریخ انتشار 2016